Majdan M, Polz M, Ksiazek A, Janicka L, Kozioł M, Swatowski A, Orłowska G
Katedry i Kliniki Nefrologii Akademii Medycznej w Lublinie.
Przegl Lek. 1995;52(6):307-10.
In 55 hemodialyzed and 15 patients on CAPD the presence of hepatitis B and C markers was estimated before the beginning of the vaccination series against hepatitis B with Engerix B vaccine. The initial anti-H Bs antibody titres was also estimated in these patients. The patients without H Bs Ag who have the anti-Hbs titres below 10 IU/I were qualified for this vaccination. The vaccination was needed by 40% of hemodialyzed patients H Bs(-) and 93% patients on CAPD. After completing the half year lasting series of vaccinations, the serological answer in vaccinated patients was estimated. The protective antibody titres above 10 IU/I was produced by 62.5% of patients on hemodialysis and 64.4% of patients on CAPD. The presence of anti-HCV antibodies had insignificant influence on the ability of producing the protective antibody titres in vaccinated patients.
在55例接受血液透析的患者和15例接受持续性不卧床腹膜透析（CAPD）的患者中，在开始使用安在时（Engerix B）疫苗进行乙肝疫苗接种系列之前，评估了乙肝和丙肝标志物的存在情况。还对这些患者的初始抗-HBs抗体滴度进行了评估。抗-HBs滴度低于10 IU/I且无HBs Ag的患者符合此次疫苗接种条件。40%的血液透析HBs(-)患者和93%的CAPD患者需要接种疫苗。在完成为期半年的疫苗接种系列后，评估了接种疫苗患者的血清学反应。血液透析患者中有62.5%、CAPD患者中有64.4%产生了高于10 IU/I的保护性抗体滴度。抗-HCV抗体的存在对接种疫苗患者产生保护性抗体滴度的能力影响不大。
